Key Highlights
- $9.5 million raised in Series A extension, led by The Cigna Group Ventures, with support from 7Wire Ventures, Define Ventures, Leaps by Bayer, and Founders Fund.
- Aiming to address the high demand and cost of GLP-1 medications for diabetes and weight management, with 48% of Americans interested in these treatments.
- Impressive clinical outcomes reported by 9amHealth, including an A1c reduction of 2.1, 14.5% body weight reduction, and high medication adherence rates among its members.
Source: PR Newswire
Notable Quotes
- “GLP-1s have caught the attention of Americans… For the first time ever, we’re seeing a significant uptick in patients who are excited about taking care of their diabetes and weight health,” – Frank Westermann, Co-Founder and Co-CEO at 9amHealth
- “9amHealth has made great strides in improving access to care for patients diagnosed with obesity and diabetes, and we are excited to help accelerate their next phase of growth,” – Craig Cimini, Head at The Cigna Group Ventures
SoHC's Take
9amHealth’s recent Series A extension funding round not only underscores the vital importance of their mission to provide affordable, high-quality care for cardiometabolic conditions but also highlights a growing recognition in the healthcare industry of the need for innovative solutions to manage chronic diseases. With a staggering number of Americans showing interest in GLP-1 medications for diabetes and weight management, the challenge of accessibility and affordability becomes ever more pertinent.
9amHealth, through its comprehensive approach that combines medication delivery, personalized care plans, and at-home lab tests, is at the forefront of addressing these challenges. Their focus on expanding access to care and managing the costs associated with expensive treatments like GLP-1s is a testament to their commitment to patient health and financial well-being. The involvement of major investors such as The Cigna Group Ventures further validates the potential impact of 9amHealth’s model on improving health outcomes for patients across the United States.
As the healthcare landscape continues to evolve, 9amHealth’s innovative approach to cardiometabolic care represents a significant step forward in making comprehensive, effective treatment more accessible to those in need. Their success in securing additional funding is a positive indicator of the value they bring to patients, employers, and the broader healthcare system.
